CN113813225B - Portable beta-FeSi 2 Composite spray hydrogel and preparation method and application thereof - Google Patents

Portable beta-FeSi 2 Composite spray hydrogel and preparation method and application thereof Download PDF

Info

Publication number
CN113813225B
CN113813225B CN202111106863.3A CN202111106863A CN113813225B CN 113813225 B CN113813225 B CN 113813225B CN 202111106863 A CN202111106863 A CN 202111106863A CN 113813225 B CN113813225 B CN 113813225B
Authority
CN
China
Prior art keywords
fesi
beta
hydrogel
sodium alginate
portable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202111106863.3A
Other languages
Chinese (zh)
Other versions
CN113813225A (en
Inventor
吴成铁
马文平
马红石
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zhongke Sifukang Jining Medical Device Technology Co ltd
Original Assignee
Zhongke Sifukang Jining Medical Device Technology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zhongke Sifukang Jining Medical Device Technology Co ltd filed Critical Zhongke Sifukang Jining Medical Device Technology Co ltd
Priority to CN202111106863.3A priority Critical patent/CN113813225B/en
Publication of CN113813225A publication Critical patent/CN113813225A/en
Application granted granted Critical
Publication of CN113813225B publication Critical patent/CN113813225B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0052—Thermotherapy; Hyperthermia; Magnetic induction; Induction heating therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/26—Iron; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14—Macromolecular materials
    • A61L27/20—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/40—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material
    • A61L27/44—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having a macromolecular matrix
    • A61L27/446—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having a macromolecular matrix with other specific inorganic fillers other than those covered by A61L27/443 or A61L27/46
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/52—Hydrogels or hydrocolloids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/56—Porous materials, e.g. foams or sponges
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/60—Materials for use in artificial skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/10—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing inorganic materials
    • A61L2300/102—Metals or metal compounds, e.g. salts such as bicarbonates, carbonates, oxides, zeolites, silicates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/412—Tissue-regenerating or healing or proliferative agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/416—Anti-neoplastic or anti-proliferative or anti-restenosis or anti-angiogenic agents, e.g. paclitaxel, sirolimus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Dermatology (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Transplantation (AREA)
  • Dispersion Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Composite Materials (AREA)
  • Materials Engineering (AREA)
  • Medicinal Preparation (AREA)

Abstract

The invention relates to portable beta-FeSi 2 Composite spray hydrogel and a preparation method and application thereof. The portable beta-FeSi 2 The composite spray hydrogel comprises: sodium alginate hydrogel and beta-FeSi dispersed in sodium alginate hydrogel 2 And (3) granules.

Description

Portable beta-FeSi 2 Composite spray hydrogel and preparation method and application thereof
Technical Field
The invention relates to a skin tumor treatment material and a wound healing material, and relates to a portable beta-FeSi 2 A composite spray hydrogel, a preparation method thereof and application thereof in preparing a skin tumor treatment material and a wound healing material belong to the field of biological materials.
Background
Melanoma is one of the common malignancies in humans. Currently, the common clinical treatments for skin cancer are surgical resection and radio/chemotherapy. However, the large-area skin defect and residual tumor cells caused by the operation and the toxic and side effects of radiotherapy/chemotherapy severely limit the treatment effect of melanoma. Based on the limitations of these traditional therapeutic approaches, researchers have proposed a series of novel cancer treatment strategies. For example, photothermal therapy (PTT) can effectively kill tumor cells, and has the characteristics of high efficiency and small toxic and side effects. Furthermore, chemokinetic therapy (CDT) achieves specific and deep tumor ablation by generating highly aggressive hydroxyl radicals (· OH) to eliminate tumor cells. Meanwhile, the treatment of skin tumor is usually accompanied by large skin defect, which brings great pain and inconvenience to the postoperative recovery of patients. One of the key challenges in solving these problems is how to accomplish rapid treatment of skin wounds and provide the patient with the most convenient treatment options possible. Therefore, the development of a novel portable bifunctional biomaterial which can effectively remove residual tumor tissues and promote skin regeneration in time is of great significance.
The treatment of skin tumors is usually accompanied by major skin defects, which cause great pain and inconvenience to the postoperative recovery of the patient. Conventional skin wound dressings are often unsatisfactory due to their complex and slow manufacturing process. It is worth noting that the sprayed hydrogel can quickly form a protective layer on the wound to prevent bacteria invasion, has the advantages of simple operation and quick in-situ action, and is very suitable for on-site emergency wound treatment. For example, in sporting events, medical personnel often provide emergency treatment to injured athletes by spraying. Spray hydrogels are becoming an important component of home drug cabinets due to their convenience and portability. For patients after excision of skin tumors, the spray hydrogel can realize the purpose of home self-recovery treatment. Therefore, it is of great interest to develop an in situ cross-linked spray hydrogel that can be used immediately for skin tumor treatment and wound healing.
Disclosure of Invention
Aiming at the problems in the prior art, the invention provides a portable beta-FeSi for the first time 2 Composite spray hydrogel, a preparation method thereof and application thereof in preparing tumor treatment materials and skin repair materials.
In a first aspect, the invention provides a portable beta-FeSi 2 Composite spray hydrogel, said portable beta-FeSi 2 The composite spray hydrogel comprises: sodium alginate hydrogel and beta-FeSi dispersed in sodium alginate hydrogel 2 And (3) particles.
In this disclosure, β -FeSi is first introduced 2 Can be used as photo-thermal agent for tumor photo-thermal treatment under near infrared light excitation. Wherein, based on the weak acidic condition and high H of the tumor site 2 O 2 Feature, beta-FeSi 2 The released Fe ions can catalyze Fenton reaction to generate OH, so that the targeted chemical kinetic treatment of the tumor microenvironment is realized. And an external thermal field formed by near infrared light excitation can promote the Fenton reaction and improve the curative effect of CDT. Thus, beta-FeSi 2 Has the PTT and CDT synergistic anti-tumor capability and great application potential.
Further, in order to promote skin regeneration, the present inventors have made an effective strategy to introduce bioactive ions to enhance the bioactivity of the composite hydrogel. The invention leads beta-FeSi to be 2 As a biological activator to improve the biological activity of the composite hydrogel. Furthermore, sodium Alginate (SA) hydrogels have many advantages, being compatible with Ca 2+ The ions are quickly and simply crosslinked, and the biocompatibility is good. Of course, the lack of bioactivity of pure SA limits its use in tissue repair.
Preferably, the concentration of the sodium alginate in the sodium alginate hydrogel is 1.0-2.5 wt%; the beta-FeSi 2 Granules andthe mass ratio of the sodium alginate is (0.01-0.2): 1.
preferably, the portable beta-FeSi 2 The composite spray hydrogel has a three-dimensional micron-sized pore structure, and the pore size distribution is 100-500 mu m.
Preferably, the beta-FeSi 2 The particles have a particle size of 15 μm or less, preferably 10 μm or less, more preferably 1 μm or less, and most preferably 500nm or less.
In a second aspect, the invention provides a portable beta-FeSi 2 The preparation method of the composite spray hydrogel comprises the step of mixing the beta-FeSi 2 Spraying the sodium alginate solution on the surface of the base material, and then spraying the calcium chloride solution to carry out in-situ crosslinking, thereby obtaining the portable beta-FeSi 2 Compounding spray hydrogel.
Preferably, the concentration of the sodium alginate in the sodium alginate solution is 1.0-2.5 wt%; the beta-FeSi 2 The mass ratio of the particles to the sodium alginate is (0.01-0.2): 1.
preferably, the sodium alginate is added into the deionized water and stirred uniformly to obtain a sodium alginate solution; then ultrasonic dispersing is carried out to lead the beta-FeSi to be 2 Dispersing the particles in sodium alginate solution to obtain the product containing beta-FeSi 2 The sodium alginate solution of (1).
Preferably, mixing calcium chloride with deionized water to obtain a calcium chloride solution; the concentration of the calcium chloride solution is 1.5-5.0 wt%.
Preferably, the spray coating contains beta-FeSi once 2 Spraying a calcium chloride solution for one time simultaneously with the sodium alginate solution; setting each spraying to contain beta-FeSi 2 The content of the sodium alginate solution is 0.01-0.05 mL/cm 2 And controlled to contain beta-FeSi 2 The spraying times of the sodium alginate solution are not more than 20.
In a third aspect, the invention provides a portable beta-FeSi 2 The application of the composite spray hydrogel in preparing skin tumor treatment materials and skin wound healing materials. When the beta-FeSi is used for preparing skin tumor treatment materials, the beta-FeSi is portable 2 The concentration of sodium alginate in the sodium alginate hydrogel in the composite spray hydrogel is 1.0-2.5 wt%, and the beta-FeSi 2 The mass ratio of the particles to the sodium alginate is (0.01-0.2): 1. when the beta-FeSi is used for preparing skin wound healing materials, the beta-FeSi is portable 2 The concentration of sodium alginate in the sodium alginate hydrogel in the composite spray hydrogel is 1.0-2.5 wt%, and the beta-FeSi 2 The mass ratio of the particles to the sodium alginate is (0.01-0.2): 1.
has the advantages that:
the invention prepares the portable beta-FeSi 2 And (3) compounding spray hydrogel. Wherein, beta-FeSi 2 Has excellent photo-thermal performance and OH generation capacity, and can realize the synergistic and efficient treatment of tumors by PTT and CDT. Meanwhile, the evaluation of endothelial cell migration, in vitro angiogenesis-related gene expression and the therapeutic effect of burn skin in vivo proves that the beta-FeSi 2 Biological activity as novel biomaterials to promote wound healing and beta-FeSi 2 The convenience and timeliness of the composite spray hydrogel for skin regeneration. Importantly, the composite spray hydrogel prepared by the invention has the advantages of simplicity and convenience in use, and is suitable for wound treatment in emergency situations such as burns. Thus, due to portability and simplicity, as well as dual function of tumor therapy and skin wound healing, β -FeSi 2 The composite spray hydrogel provides a portable treatment method for patients after excision of skin tumors.
Drawings
FIG. 1 shows beta-FeSi 2 A crystalline phase and microstructure of the particles, wherein (a) beta-FeSi 2 XRD pattern of (b) beta-FeSi 2 SEM image of (d). FIG. 1 shows that FeSi is synthesized 2 Is in the beta crystalline phase, consistent with expectations, and the crystallinity is good. The scanning electron microscope image shows that the particles are irregular particles with the particle size of about 10 mu m.
FIG. 2 shows beta-FeSi 2 The photothermal and chemico-kinetic property test of (a), wherein (a) different power densities (0.30W/cm) 2 、0.45W/cm 2 And 0.60W/cm 2 ) 808nm laser irradiation for 800s, and beta-FeSi was measured 2 Photothermal temperature profile of aqueous dispersion (2.5 mg/mL). (b) Different beta-FeSi 2 U content after 24h incubation of Tris-HCl extract (24 h) with TMB (pH = 6.0)V-vis absorption spectra, in which the absorbance of the label "4-7" is low. In FIG. 2, beta-FeSi is shown 2 Has excellent photo-thermal performance and chemical kinetic property, and can be used as a novel antitumor agent.
FIG. 3 is a view showing β -FeSi 2 Preparation, shape and thickness control of composite spray hydrogel, wherein (a-d) beta-FeSi 2 Preparation of composite spray hydrogel, (e-h) different beta-FeSi 2 Appearance photos and micro-appearances of four groups of spray hydrogel with different contents, (i-l) different beta-FeSi under high power 2 SEM images of four sets of spray hydrogels for content, (m) hydrogel thickness statistics. In FIG. 3, beta-FeSi is shown 2 The composite spray hydrogel has the characteristic of rapid in-situ gelation and is accompanied with beta-FeSi 2 The content of (a) increases, and the color of the hydrogel becomes darker. The scanning electron microscope image shows that the beta-FeSi has a micron-order pore structure 2 The shape of the porous material is not influenced by the addition of the (B), and the particles are distributed in the pore wall. In addition, the thickness of the hydrogel can be controlled by controlling the number of times of ejection.
FIGS. 4 and 5 are beta-FeSi 2 Photothermal performance testing of composite spray hydrogels, where FIG. 4 represents different β -FeSi 2 The content of the four groups of spray type composite hydrogel is measured at the laser power density (0.60W/cm) 2 ) Temperature change curve of 10 minutes of irradiation (wet state: soaking in 300 μ L deionized water); FIG. 5 shows different laser power densities (0.30, 0.45, 0.60 and 0.75W/cm) for the SA-10FS group hydrogels 2 ) Photo-thermal temperature rise curve of 10 min of irradiation. FIG. 6 shows β -FeSi 2 The chemical dynamic property test of the composite hydrogel shows that different beta-FeSi 2 Content of Tris-HCl extract of composite hydrogel (24 h) UV-vis absorbance spectra after 24h incubation with TMB (pH = 6.0), with very low absorbance labeled "5-7". The results show that the composite hydrogel is prepared from beta-FeSi 2 Has excellent photothermal temperature rising characteristics and OH generating ability.
FIG. 7 shows β -FeSi 2 In vitro anti-tumor experiments of composite spray hydrogel, wherein (a) the survival rate of skin tumor cells B16F10 under different treatment conditions, (B) live and dead staining of B16F10 cells under different intervention conditions, (c) B16F10 intracellular OHThe detection of (3). In FIG. 7, beta-FeSi is shown 2 The composite spray hydrogel has good effect of treating skin tumor in vitro, and can kill tumor cells through the cooperation of PTT and CDT.
FIG. 8 shows beta-FeSi 2 The composite spray hydrogel is used for treating skin tumor in vivo, wherein (a) a mouse thermal imaging picture, (b) an optical picture of nude mice at day 0 and day 12, and (c) a relative tumor volume change curve within day 12. In FIG. 8, beta-FeSi is shown 2 The composite spray hydrogel can be used for synergistically treating skin tumors through PTT and CDT, and effectively inhibiting the growth of the tumors.
FIG. 9 shows H of tumor tissues of different treatment groups&And E, dyeing results. In combination with FIG. 9, the combination shows β -FeSi 2 The composite spray hydrogel can be used for synergistically treating skin tumors through PTT and CDT, and effectively inhibiting the growth of the tumors.
FIG. 10 shows beta-FeSi 2 In vitro bioactivity test of the composite spray hydrogel, wherein (a) the proliferation of HUVECs, (b) the proliferation of HDFs, (c) migration statistics of HUVECs, and (d) optical photographs of the migration of HUVECs. In FIG. 10, beta-FeSi is shown 2 The composite spray hydrogel has good biocompatibility, can obviously promote the migration of endothelial cells, and shows excellent bioactivity.
FIG. 11 shows beta-FeSi 2 The in vitro angiogenesis promoting capability test of the composite spray hydrogel comprises the steps of (a) dividing HIF-1 alpha, VEGF, KDR and eNOS gene expression in endothelial cells, and (e) staining CD31 protein. Fig. 11 shows that the beta-FeSi 2 composite spray hydrogel can significantly promote the expression of angiogenesis-related genes, and the CD31 protein staining also shows that the hydrogel has excellent in vitro angiogenesis ability and is important for skin repair.
FIG. 12 is a test of scald treatment on mice skin in vivo, wherein (a) the scald treatment process, (b) the wound closure rate statistics, (c) the wound surface pictures at different time points, and (d) the new skin H&E staining, (E) neovascularization in neodermis. In FIG. 12, beta-FeSi is shown 2 The composite spray hydrogel can be quickly used for treating skin wounds, has the advantages of simple operation, convenient treatment, portability and the like, and has good skin repairing function according to the wound healing conditionEnergy, in addition, β -FeSi compared to blank and pure sodium alginate groups 2 The composite spray hydrogel has remarkable angiogenesis promoting capability.
Detailed Description
The present invention is further illustrated by the following examples, which are to be understood as merely illustrative and not restrictive.
The inventor utilizes the photo-thermal conversion and chemical dynamic characteristics of a semiconductor iron-containing material and beta-FeSi for the first time 2 The elements contained are all bioactive ions, and the consideration is that the beta-FeSi 2 The composite spray hydrogel is used for treating skin tumor and healing wound surface.
In this disclosure, portable beta-FeSi 2 The composite spray hydrogel is a three-dimensional porous structure, and has the advantages of portability, simple operation and convenient use. The chemical composition of which comprises sodium alginate and beta-FeSi 2 . Among them, the beta-FeSi in the present invention 2 The specific synthesis method of the powder can be found in the literature (X.Du, P.Qiu, J.Chai, T.Mao, P.Hu, J.Y ang, Y.Y.Sun, X.Shi, L.Chen, double Thermoelectric Figure of Merit in p-Type beta-FeSi) 2 via Synergistically Optimizing Electrical and Thermal Transports,ACS Appl.Mater.Interfaces 12(11)(2020)12901-12909)。
In an alternative embodiment, the concentration of sodium alginate in the sodium alginate hydrogel may be between 1.0 and 2.5wt%. The beta-FeSi 2 The mass ratio of the particles to the sodium alginate is (0.01-0.2): 1. as an example, the stoichiometric composition of the sodium alginate is pure sodium alginate (1.5 wt%), 2wt% beta-FeSi 2 Sodium alginate, 5wt% beta-FeSi 2 Sodium alginate, 10wt% beta-FeSi 2 Sodium alginate, abbreviated as SA, SA-2FS, SA-5FS, SA-10FS, respectively. beta-FeSi of the invention 2 The composite spray hydrogel has a three-dimensional micron-order pore structure, and beta-FeSi 2 The addition of (A) does not affect the morphology.
In the invention, the obtained beta-FeSi 2 The composite spray hydrogel can be quickly gelatinized at a target part; beta-FeSi 2 The composite spray hydrogel can be used as a novel bifunctional material and not only can be used as a skinCan be used for treating skin tumor, and promoting skin wound healing. In addition, the wound healing device can realize rapid treatment of the wound surface in emergency, and provides a portable therapy for wound treatment in families, fields and the like.
In one embodiment of the present invention, the portable beta-FeSi 2 The preparation method of the composite spray hydrogel has the advantages of simple operation and convenient preparation. The following is an exemplary illustration of β -FeSi 2 A preparation method of composite spray hydrogel.
Dispersing beta-FeSi by using ultrasonic 2 Dispersing in sodium alginate solution to obtain the product containing beta-FeSi 2 The sodium alginate solution of (1). As an example, a mass of sodium alginate is added to deionized water and stirred overnight to give a 1.5wt.% sodium alginate solution; then dispersing the beta-FeSi with different mass fractions by using ultrasound 2 Dispersed in sodium alginate solution as solution A. The sodium alginate has high viscosity and molecular weight of 30000-210000.
Mixing calcium chloride and deionized water to obtain a calcium chloride solution. As an example, calcium chloride and deionized water were mixed in a mass ratio of 3: 97, and stirred to obtain a 3wt.% calcium chloride solution as solution B. The calcium chloride can be anhydrous calcium chloride.
By separately ejecting a liquid containing beta-FeSi 2 The sodium alginate solution and the calcium chloride solution are subjected to in-situ rapid crosslinking to form hydrogel. As an example, solution A is sprayed on a glass sheet, and then solution B is sprayed to form hydrogel in situ through rapid crosslinking.
In alternative embodiments, the thickness of the composite hydrogel can be controlled by controlling the number of ejections (e.g., can be 200 μm to 1.5 mm). In addition, hydrogel materials with uniform thickness and size are prepared by means of a puncher. Setting each spraying to contain beta-FeSi 2 The content of the sodium alginate solution is 0.01-0.05 mL/cm 2 The spraying times are controlled to be less than 20 times, and the calcium ion diffusion crosslinking limit is avoided being exceeded.
In the invention, the obtained beta-FeSi 2 The composite spray hydrogel is simple to prepare and operate, and is portable and convenient to use for treating skin tumorApplication in the treatment and wound healing materials.
beta-FeSi of the invention 2 The composite spray hydrogel has the characteristic of rapid gelation, excellent in-vitro anti-tumor effect and good biological activity, and animal experiments prove that the beta-FeSi 2 The composite spray hydrogel has excellent double functions of treating skin tumors and promoting skin wound healing. Thus, beta-FeSi 2 The composite spray hydrogel is a novel bifunctional biological material, and the spraying method has the advantages of simple operation, portability and the like, and provides a new idea and a new method for rapidly treating emergency wounds in families, fields and the like.
β-FeSi 2 The crystal form and the appearance are characterized:
according to the invention, the beta-FeSi in the invention can be known through Scanning Electron Microscope (SEM) and X-ray diffraction (XRD) 2 The beta phase has good crystallinity and has a particle size of about 10 μm (see, for example, FIG. 1).
β-FeSi 2 The performance characterization of (2):
the beta-FeSi in the invention can be known by means of photo-thermal performance test, OH generation detection and the like 2 Has good photo-thermal and chemical dynamic properties, and can be used as a novel antitumor agent (see, for example, FIG. 2).
β-FeSi 2 Preparation of composite spray hydrogel:
the invention comprises beta-FeSi by respectively spraying 2 The sodium alginate solution and the calcium chloride solution of (a) rapidly cross-link them in situ to form a hydrogel (see, e.g., figure 3).
Para beta-FeSi 2 The morphology and thickness control research of the composite spray hydrogel comprises the following steps:
the invention researches different beta-FeSi 2 The micro-morphology of the composite hydrogel. The result shows that the material has a porous three-dimensional network structure, beta-FeSi 2 The appearance is not influenced by adding the beta-FeSi 2 particles, and the beta-FeSi 2 particles are dispersed in the inner part of the hole wall. In addition, by controlling the number of times of ejection, the thickness of the hydrogel can be adjusted, the number of times of ejection is less than 15, the thickness is almost linear with the number of times, and when the number of times of ejection is more than 15, the thickness is slightly reduced because of Ca 2+ Limited diffusion limits crosslinking (see, e.g., fig. 3).
β-FeSi 2 Performance study of the composite spray hydrogel:
the invention researches four groups of different beta-FeSi 2 The content of the hydrogel has the photo-thermal property and the chemical-dynamic property. The results show that the final temperature of the hydrogel gradually increases with increasing FS content under the same laser power irradiation. However, the pure SA group had no significant photothermal effect. The temperature change of the same group of composite hydrogel can be controlled by the power density of the near-infrared laser. At 0.30-0.75W/cm 2 After 10 minutes of irradiation at the laser power of (2), there was a significant difference in the maximum temperature of the SA-10FS hydrogel. Furthermore, the generation of OH in four groups of SA, SA-2FS, SA-5FS and SA-10FS was examined using TMB. Three groups of SA-2FS, SA-5FS and SA-10FS all have obvious absorption peaks near 652 nm. SA-10FS has the greatest absorbance due to the highest iron content, indicating the strongest ability to produce OH (see, e.g., FIGS. 4-6).
β-FeSi 2 The in vitro anti-tumor effect of the composite spray hydrogel is as follows:
the invention proves that the beta-FeSi is firstly 2 The composite spray hydrogel has excellent performance of treating skin tumor in vitro through the cooperation of PTT and CDT. Cell viability of B16F10 cells under different conditions of pH =7.4 and pH =6.0 showed that, first, the viability of B16F10 cells was 97.7% and 31.2% at pH =7.4 for the SA-10FS group and the SA-10fs +47 ℃ group, respectively, demonstrating that the SA-10FS hydrogel in-vitro photothermal therapy was effective. Secondly, at pH =6.0, SA-10FS +47 ℃ + H, compared with SA-10FS +47 ℃ + 2 O 2 The group B16F10 cell viability was reduced to 12.5% due to the significant synergistic efficiency of CDT and PTT in vitro, and it was shown that high temperature can significantly increase the effectiveness of CDT. As a control, pure CDT set (SA-10FS +H) 2 O 2 Group, pH = 6.0) cell viability was normal (99.3%), indicating that CDT alone had essentially no therapeutic effect. To further enhance the synergistic effect of PTT and CDT, the temperature was increased to 52 ℃ by adjusting the laser power density. The results indicate that the synergistic treatment group had 52 deg.C (SA-10FS +52 deg.C + H 2 O 2 pH = 6.0) is more synergistically effective than at 47 deg.CTherapy group (SA-10FS +H 2 O 2 pH = 6.0) was significantly reduced, determining the most effective treatment temperature. Subsequently, live/dead staining images visually confirmed that the co-treatment of CDT and PTT was significantly effective. Next, the SA-10FS hydrogel was further evaluated for intracellular OH production. At pH =6.0 with SA-10FS +H 2 O 2 The incubated B16F10 cells showed strong green luminescence. In contrast, high temperature group (SA-10FS +47 ℃ + H 2 O 2 And SA-10FS +52 deg.C + H 2 O 2 ) More pronounced green luminescence occurs, demonstrating that increasing temperature favors intracellular OH production (see, e.g., FIG. 7).
β-FeSi 2 Study of skin tumor treatment in composite spray hydrogel:
nude mice bearing B16F10 tumors were selected to evaluate the in vivo therapeutic potential of the composite hydrogels. A mouse thermal imaging photo shows that the temperature of a tumor part can quickly reach about 52 ℃ under the laser irradiation of the SA-10FS + NIR group, and the temperature of the SA + NIR group is only kept below 37 ℃ under the same laser irradiation, so that the feasibility of PTT is shown. Statistics of relative tumor volumes during 12 days and photographs of mice after 12 days all show that tumor growth is severely inhibited in the SA-10FS + NIR group alone, skin wounds have nearly healed, validating the high efficiency of PTT and CDT. However, tumors grew rapidly in all four other groups. Tumor tissue H & E staining further indicated that tumor growth was significantly inhibited in the SA-10FS + NIR group, and the tumor internal structure was incomplete, showing obvious signs of tumor cell necrosis. In contrast, four other groups of tumors were intact with extremely dense and intact nuclear structures (see, e.g., fig. 8, fig. 9).
β-FeSi 2 The in vitro biological activity and angiogenesis promoting capability of the composite spray hydrogel are researched:
HUVECs and HDFs were treated with four different sets of beta-FeSi 2 Culturing the hydrogel leaching liquor for 1, 3 and 5 days. CCK-8 analysis results prove that the beta-FeSi 2 The released ions have no cytotoxicity on HUVECs and HDFs, and the composite hydrogel has good biocompatibility. Subsequently, from the results of the migration of endothelial cells, it was found that a certain amount of β -FeSi was contained 2 Is hydraulicThe colloidal leaching solution has a remarkable promotion effect on the migration of HUVECs. Furthermore, beta-FeSi 2 The composite hydrogel leaching liquor can remarkably up-regulate the expression of HUVECs angiogenesis related genes VEGF, HIF-1 alpha, KDR and eNOS, which indicates that beta-FeSi 2 The released ions have a certain in vitro pro-angiogenic capacity. To further demonstrate their ability to vascularize, we performed CD31 immunofluorescent protein staining of cells cultured for 3 days with SA-10FS hydrogel extracts, and the SA-10FS group showed significantly high expression of CD31 protein compared to the blank and SA groups (see, e.g., fig. 10, fig. 11).
β-FeSi 2 The compound spray hydrogel has the following effects of treating the skin scald of the white mouse in vivo:
further confirmation of beta-FeSi by creating an in vivo skin scald model 2 The in vivo bioactivity of the composite spray hydrogel. The characteristics of simple operation, convenient use and timeliness of the spraying method are shown in the treatment process of the scald. The change result of the wound size within 14 days shows that the SA-10FS hydrogel has obvious promotion effect on wound healing compared with the blank group and the SA group. In addition, skin samples after 14 days were passed through H&E and CD31 staining for analysis. From H&E staining it can be seen that SA-10FS has healed completely, showing good re-epithelialization, while the blanks and SA groups still have scars. As can be seen from the CD31 immunofluorescence staining result, the SA-10FS group wound tissue CD31 positive expression is obviously higher than that of the other two groups. In addition, statistics of new blood vessels in three groups of dermis also show that beta-FeSi 2 Has a significant effect on promoting angiogenesis in the wound healing process (see, for example, FIG. 12).
The present invention will be described in detail by way of examples. It is also to be understood that the following examples are illustrative of the present invention and are not to be construed as limiting the scope of the invention, and that certain insubstantial modifications and adaptations of the invention by those skilled in the art may be made in light of the above teachings. The specific process parameters and the like of the following examples are also only one example of suitable ranges, i.e., those skilled in the art can select the appropriate ranges through the description herein, and are not limited to the specific values exemplified below. The spraying equipment used in the invention is a 5mL throat spray bottle (short rocker, outlet diameter: 0.5 mm); 20mL of a conventional side spray bottle (outlet diameter: 0.75 mm).
Example 1
(1) On the surface of the glass substrate, the mixture is sprayed by the spray nozzle containing beta-FeSi 2 Sodium alginate solution (beta-FeSi) 2 5wt.% of particles and sodium alginate) and 3wt.% of calcium chloride solution, which are crosslinked in situ to form a hydrogel (SA-5 FS). Each spray coating contains beta-FeSi 2 The content of the sodium alginate solution is 0.025mL/cm 2 The thickness of the material is 1mm by regulating and controlling the spraying times (10-12 times);
(2) The prepared composite hydrogel is subjected to morphology analysis, and the influence of the spraying times on the thickness of the hydrogel is researched, and the result is shown in FIG. 3;
(3) p-beta-FeSi 2 The photothermal and chemokinetic properties of the composite spray hydrogel (SA-5 FS) were studied, as described above, and the results are shown in FIGS. 4 to 6.
Example 2
(1) On the surface of the glass substrate, the mixture is sprayed by a nozzle containing beta-FeSi 2 Sodium alginate solution (beta-FeSi) 2 10wt.% of particles and sodium alginate) and 3wt.% of calcium chloride solution, and crosslinking the particles in situ to form a hydrogel (SA-10 FS). Each spray coating contains beta-FeSi 2 The content of the sodium alginate solution is 0.02mL/cm 2 The thickness of the ink is 1mm by regulating and controlling the spraying times (11-13 times);
(2) The capacity of the prepared composite hydrogel for removing tumor cells in vitro through PTT and CDT is researched, and the result is shown in figure 7;
(3) Exploring beta-FeSi 2 The in vivo tumor treatment effect of the composite spray hydrogel (SA-10 FS) was shown in FIG. 8 and FIG. 9.
Example 3
(1) On the surface of the glass substrate, the mixture is sprayed by the spray nozzle containing beta-FeSi 2 Sodium alginate solution (beta-FeSi) 2 10wt.% of particles and sodium alginate) and 3wt.% of calcium chloride solution, which are crosslinked in situ to form a hydrogel (SA-10 FS). Each timeThe secondary spraying contains beta-FeSi 2 The content of the sodium alginate solution is 0.02mL/cm 2 The thickness of the ink is 1mm by the spraying times (11-13 times);
(2) The prepared composite hydrogel was evaluated for in vitro bioactivity, and the results are shown in fig. 10;
(3) p-beta-FeSi 2 The in vitro angiogenesis promoting capacity of the composite spray hydrogel was investigated, and the results are shown in fig. 11;
(4) Explores beta-FeSi 2 The in vivo skin scald treatment effect of the composite spray hydrogel (SA-10 FS) is shown in FIG. 12.
Example 4
On the surface of the glass substrate, the mixture is sprayed by a nozzle containing beta-FeSi 2 Sodium alginate solution (beta-FeSi) 2 The mass ratio of particles and sodium alginate was 2 wt.%) and 3wt.% calcium chloride solution, which were cross-linked in situ to form a hydrogel (SA-2 FS). Each spray coating contains beta-FeSi 2 The content of the sodium alginate solution is 0.03mL/cm 2 The thickness of the ink is 1mm by regulating and controlling the spraying times (8-10 times).
Comparative example 1
Pure sodium alginate hydrogel was used as a control: on the surface of the glass substrate, 1.5wt.% pure sodium alginate solution and 3wt.% calcium chloride solution are respectively sprayed out to be rapidly crosslinked in situ to form hydrogel (SA).

Claims (11)

1. Portable beta-FeSi 2 The composite spray hydrogel is characterized in that the portable beta-FeSi 2 The composite spray hydrogel comprises: sodium alginate hydrogel and beta-FeSi dispersed in sodium alginate hydrogel 2 Particles; wherein will contain beta-FeSi 2 Spraying the sodium alginate solution on the surface of the base material, and then spraying the calcium chloride solution to carry out in-situ crosslinking, thereby obtaining the portable beta-FeSi 2 And (3) compounding spray hydrogel.
2. The portable β -FeSi according to claim 1 2 The composite spray hydrogel is characterized in that the sodium alginate in the sodium alginate solution isThe concentration is 1.0-2.5 wt%; the beta-FeSi 2 The mass ratio of the particles to the sodium alginate is (0.01-0.2): 1.
3. the portable β -FeSi according to claim 1 2 The composite spray hydrogel is characterized in that the portable beta-FeSi 2 The composite spray hydrogel has a three-dimensional micron-sized pore structure, and the pore size distribution is 100-500 mu m.
4. The portable β -FeSi according to claim 1 2 The composite spray hydrogel is characterized in that the beta-FeSi is 2 The particle size of the particles is less than or equal to 15 mu m.
5. The portable beta-FeSi according to claim 4 2 The composite spray hydrogel is characterized in that the beta-FeSi is 2 The particle size of the particles is less than or equal to 10 mu m.
6. The portable β -FeSi of claim 5 2 Composite spray hydrogel, characterized in that the beta-FeSi 2 The particle size of the particles is less than or equal to 1 mu m.
7. The portable β -FeSi of claim 6 2 The composite spray hydrogel is characterized in that the beta-FeSi is 2 The particle size of the particles is less than or equal to 500nm.
8. The portable β -FeSi according to claim 1 2 The composite spray hydrogel is characterized in that sodium alginate is added into deionized water and stirred uniformly to obtain a sodium alginate solution; ultrasonically dispersing the beta-FeSi 2 Dispersing the particles in sodium alginate solution to obtain the product containing beta-FeSi 2 The sodium alginate solution of (1).
9. The portable β -FeSi according to claim 1 2 The composite spray hydrogel is characterized in that calcium chloride is mixed with deionized water to obtain a calcium chloride solution; the concentration of the calcium chloride solution is 1.5 to5.0wt%。
10. The portable beta-FeSi according to claim 1 2 The composite spray hydrogel is characterized by containing beta-FeSi once per spraying 2 Spraying a calcium chloride solution for the first time; setting each spraying to contain beta-FeSi 2 The content of the sodium alginate solution is 0.01-0.05 mL/cm 2 And controlled to contain beta-FeSi 2 The spraying times of the sodium alginate solution are not more than 20.
11. A portable β -FeSi according to any one of claims 1 to 10 2 The application of the composite spray hydrogel in preparing skin tumor treatment materials and skin wound healing materials.
CN202111106863.3A 2021-09-22 2021-09-22 Portable beta-FeSi 2 Composite spray hydrogel and preparation method and application thereof Active CN113813225B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202111106863.3A CN113813225B (en) 2021-09-22 2021-09-22 Portable beta-FeSi 2 Composite spray hydrogel and preparation method and application thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202111106863.3A CN113813225B (en) 2021-09-22 2021-09-22 Portable beta-FeSi 2 Composite spray hydrogel and preparation method and application thereof

Publications (2)

Publication Number Publication Date
CN113813225A CN113813225A (en) 2021-12-21
CN113813225B true CN113813225B (en) 2023-01-10

Family

ID=78915120

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202111106863.3A Active CN113813225B (en) 2021-09-22 2021-09-22 Portable beta-FeSi 2 Composite spray hydrogel and preparation method and application thereof

Country Status (1)

Country Link
CN (1) CN113813225B (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114984303B (en) * 2022-07-01 2023-08-29 西南交通大学 Spray type hydrogel dressing capable of generating oxygen in situ, preparation method and application

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106867040A (en) * 2017-02-28 2017-06-20 南京大学 A kind of β FeSi2Nanometer hexahedron particle Chitosan Composites and preparation method
CN110698692A (en) * 2019-10-28 2020-01-17 四川大学 Preparation method and application of self-healing sodium alginate/gelatin-based hydrogel material capable of spraying to form film
WO2020180202A1 (en) * 2019-03-01 2020-09-10 Николай Валерьевич ХОХЛОВ Composition based on cerium dioxide nanoparticles and brown algae polysaccharides for wound treatment
CN112080018A (en) * 2020-09-01 2020-12-15 湖北工业大学 Spray flowing gel and preparation method thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106867040A (en) * 2017-02-28 2017-06-20 南京大学 A kind of β FeSi2Nanometer hexahedron particle Chitosan Composites and preparation method
WO2020180202A1 (en) * 2019-03-01 2020-09-10 Николай Валерьевич ХОХЛОВ Composition based on cerium dioxide nanoparticles and brown algae polysaccharides for wound treatment
CN110698692A (en) * 2019-10-28 2020-01-17 四川大学 Preparation method and application of self-healing sodium alginate/gelatin-based hydrogel material capable of spraying to form film
CN112080018A (en) * 2020-09-01 2020-12-15 湖北工业大学 Spray flowing gel and preparation method thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Green and Kilogram-Scale Synthesis of Fe Hydrogel for Photothermal Therapy of Tumors in Vivo;Guangchao Xie等;《ACS Biomater. Sci. Eng.》;20200609;第6卷;第4276-4284页 *
Removal and recovery of heavy metals from soil with sodium alginate coated FeSSi nanocomposites in a leaching process;Bin Wu等;《Journal of Hazardous Materials》;20200516;第1-11页 *
光热转换材料及其在脱盐领域的应用;郭星星等;《化学进展》;20190115;第580-596页 *

Also Published As

Publication number Publication date
CN113813225A (en) 2021-12-21

Similar Documents

Publication Publication Date Title
Li et al. Construction of multifunctional hydrogel based on the tannic acid-metal coating decorated MoS2 dual nanozyme for bacteria-infected wound healing
Chang et al. A multifunctional cascade bioreactor based on hollow‐structured Cu2MoS4 for synergetic cancer chemo‐dynamic therapy/starvation therapy/phototherapy/immunotherapy with remarkably enhanced efficacy
Niu et al. A multifunctional bioactive glass-ceramic nanodrug for post-surgical infection/cancer therapy-tissue regeneration
Zhang et al. Near-infrared-triggered in situ hybrid hydrogel system for synergistic cancer therapy
CN104548095B (en) A kind of PLGA/MoS2Composite medicament stent material and its preparation method and application
CN113813225B (en) Portable beta-FeSi 2 Composite spray hydrogel and preparation method and application thereof
CN108815525B (en) Multifunctional polypyrrole-coated drug-loaded mesoporous titanium dioxide nanoparticle and preparation method thereof
CN111228484B (en) Application of xonotlite and composite biological material containing xonotlite
CN113084188B (en) Multifunctional therapeutic biological material and preparation method thereof
CN109276537B (en) Composite hydrogel co-loaded with vascular disrupting agent and near-infrared photothermal response nanoparticles, and preparation and application thereof
CN110038128A (en) A kind of Au@Se@Pt-Ce6 nanometer compound probe and preparation method thereof
Chu et al. Silica-supported near-infrared carbon dots and bicarbonate nanoplatform for triple synergistic sterilization and wound healing promotion therapy
Pan et al. Mesoporous porphyrinic metal-organic framework nanoparticles/3D nanofibrous scaffold as a versatile platform for bone tumor therapy
CN114984303A (en) Spray type hydrogel dressing capable of generating oxygen in situ, preparation method and application
CN116059360A (en) Intelligent near infrared light response composite hydrogel based on black phosphorus nano-sheet and preparation method and application thereof
Zhang et al. A multifunctional nano-hydroxyapatite/MXene scaffold for the photothermal/dynamic treatment of bone tumours and simultaneous tissue regeneration
Li et al. Near-infrared-induced IR780-loaded PLGA nanoparticles for photothermal therapy to treat breast cancer metastasis in bones
CN112891537A (en) Photoelectric spinning fibrous membrane with anti-tumor function and preparation method and application thereof
CN115154656B (en) Black phosphorus/bioactive glass anti-tumor bone repair dual-function composite stent and preparation method and application thereof
CN107233572B (en) Preparation method and application of photothermal agent based on amyloid polypeptide as template
CN108653805B (en) Calcium-silicon-based composite bone cement with photothermal effect and preparation method and application thereof
CN116098999A (en) TiO 2-x @GLNPs and application thereof
CN110101901B (en) Copper silicate hollow microsphere composite fiber scaffold and preparation method and application thereof
CN113713169B (en) Near-infrared light-sensitive ZIF8 functionalized gelatin nanofiber scaffold system and application thereof
Xiao et al. Piezo-enhanced near infrared photocatalytic nanoheterojunction integrated injectable biopolymer hydrogel for anti-osteosarcoma and osteogenesis combination therapy

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20220608

Address after: 272004 plant 1, building B, Zhongke scientific innovation park, the intersection of Shanhe road and Rongchang Road, Liuxing street, high tech Zone, Jining City, Shandong Province

Applicant after: Zhongke sifukang (Jining) medical device technology Co.,Ltd.

Address before: 200050 No. 1295 Dingxi Road, Shanghai, Changning District

Applicant before: SHANGHAI INSTITUTE OF CERAMICS, CHINESE ACADEMY OF SCIENCES

GR01 Patent grant
GR01 Patent grant